Semaglutide and heart disease risk markers in children with severe obesity
Looks at how semaglutide affects disease risk markers in young teens with severe obesity.
Key facts
- Who runs it
- John Bauer
- Where
- Lexington, United StatesSee the site
- Trial code
- Registry title
- Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 12 Jun 2025
- Expected to end
- Jul 2028
- Type of study
- Observational
- Treatments tested
- Ozempic®
- Record updated
- 21 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teens with class 2 or 3 obesity who are seen at the University of Kentucky Pediatric High BMI Clinic and can take semaglutide for weight loss.
- Age
- 12 to 17 years (the summary mentions ages 12-15).
- Sex
- Girls and boys can join.
- Disease stage
- Obesity class 2 or class 3.
- Earlier treatment
- Cannot join if now taking prescribed anti-obesity medicines or blood pressure medicines. No systemic steroids for longer than 3 months or in the last month.
Main reasons for not taking part
- Current anti-obesity or blood pressure medicines
- Kidney disease, liver disease or congenital disease
- Active infection at enrollment
- Genetic syndrome or congenital abnormality linked to obesity
- Pregnancy, or personal or family history of medullary thyroid carcinoma
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patient seen at University of Kentucky Pediatric High BMI Clinic
- Diagnosis of Obesity Class 2 or 3
- Meeting the clinical criteria for the medical intervention with semaglutide for weight loss
Who cannot take part
- Any current prescribed anti-obesity medications (AOM) such as Orlistat, Phentermine, Qsymia (Phentermine/Topiramate), Liraglutide, Semaglutide, and Setmelanotide
- Any current prescribed anti-hypertensive medications
- Any systemic steroid use longer than 3 month use or within the last month before enrollment (not including inhaled, ophthalmic, intranasal, and topical)
- Any specific end-organ acute concerns (kidney disease, liver disease, congenital disease)
- Any active infections at enrollment
- Any congenital abnormality or genetic syndrome known to be associated with obesity
- Personal or family history of medullary thyroid carcinoma (per product insert)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (per product insert)
- Any limitations that would make exercise testing not possible
- Pregnancy
- Inability to receive an MRI
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Where in United States
- University of KentuckyLexington, United StatesContact: Amanda Wilburn, BA CCRPTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:
Read full original descriptionShow less
* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? * Are there differences in the above factors between males and females and are there key factors to help improve the outcomes?
Participants will be given semaglutide for this study. During the course of the study, participants will:
* have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) * have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured * have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) * have follow up visits with the study doctor * be asked to take a pregnancy test if they are female and have started menstruation
The group in the trial
- Treatment Group
All participants in this study will be given the study drug.
Treatment: Ozempic®
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (MODERN)
- Plain-language title
- Semaglutide and heart disease risk markers in children with severe obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06967389, who can take part
- Record updated
- 21 July 2026